Dr. Bryan K. Hong, M.D.
Retina Specialist (Retina Specialist (Ophthalmology) Physician)
67 Belmont St, Suite 302
Worcester, MA 01605
Who else practices at this address →
Worcester County includes primary care (3% of residents) and mental health (11% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Yale University School of Medicine (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 1,029
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: Yale University School of Medicine
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Retina Specialist (Ophthalmology) Physician primary
MA license 266316 -
Ophthalmology Physician
MA license 266316
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Umass Memorial Medical Center/university Campus Worcester, MA
Medical groups
- Lexington Eye Associates, Inc (34 clinicians)
- Lexington Eye Associates - Bid (34 clinicians)
- Vitreo-Retinal Associates PC (5 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,029
- Services billed
- 49,038
- Patients’ average age
- 79
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 21,240 | 97 |
| Imaging of retina | 2,762 | 1,088 |
| Injection, aflibercept, 1 mg | 2,001 | 268 |
| Injection of drug into eye | 1,931 | 555 |
| Injection, bevacizumab, 10 mg | 790 | 244 |
| Established patient problem focused exam of visual system | 604 | 468 |
| Injection, ranibizumab, 0.1 mg | 482 | 32 |
| Established patient complete exam of visual system | 455 | 452 |
| New patient complete exam of visual system | 90 | 90 |
| Photography of the retina | 60 | 59 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Worcester, MA | 68 |
| Timolol Maleate Other prescribers in Worcester, MA | 61 |
| Latanoprost Other prescribers in Worcester, MA | 32 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Worcester, MA | 28 |
| Ofloxacin Other prescribers in Worcester, MA | 19 |
| Ketorolac Tromethamine Other prescribers in Worcester, MA | 18 |
| Brimonidine Tartrate Other prescribers in Worcester, MA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 10 payments worth $434 in total to this clinician.
| Astellas Pharma US Inc | $181 |
|---|---|
| Dutch Ophthalmic, USA | $126 |
| Genentech USA, Inc. | $78.31 |
| Regeneron Healthcare Solutions, Inc. | $49.60 |
| Food and Beverage | $434 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $3,009 in research payments for these studies, mostly to the institutions running them.
- Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU)
AbbVie Inc. - Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.